EAS is pleased to announce that Professor Philip Barter, Australia, will be the recipient of the Anitschkow Prize 2011. This prestigious Prize, awarded annually by EAS, recognizes outstanding research in the field of atherosclerosis and linked metabolic disturbances.
About the Laureate Professor Philip Barter
Professor Phil Barter is currently the Director of The Heart Research Institute in Sydney, Australia. With a longstanding research focus on the diagnosis, pathogenesis, and therapy of atherosclerosis risk factors, he is a leading example of a from-bench-to-bedside researcher. Since the 1970s, his pioneering work has significantly advanced the understanding of plasma lipoprotein metabolism, especially HDL, through both basic and clinical research. With over 170 original publications and more than 50 review papers, his work has been cited over 5,000 times, ranking him among the top 1% of most frequently cited scientists in clinical sciences.
Barter was one of the first to describe the activity of cholesteryl ester transfer protein (CETP), which has since become a target for anti-atherogenic therapies. His contributions to CETP research have played a crucial role in large randomized trials investigating the efficacy of CETP inhibitors like torcetrapib and dalcetrapib. His research on HDL’s functions beyond reverse cholesterol transport, such as its role in suppressing endothelial inflammation, has been groundbreaking.
In addition to his research, Professor Barter is an influential educator, mentoring the next generation of atherosclerosis researchers, including notable figures in the field. His leadership in global atherosclerosis research is reflected in his involvement with several international organizations and editorial roles for prominent journals, including Atherosclerosis and ATVB.
